Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Pharmacyclics Company Profile (NASDAQ:PCYC)

Consensus Ratings for Pharmacyclics (NASDAQ:PCYC) (?)
Ratings Breakdown: 5 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.62)
Consensus Price Target: $156.93 (13.19% upside)

Current Analysts' Coverage Summary for Pharmacyclics (NASDAQ:PCYC)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/6/2014ZacksReiterated RatingNeutral -> Neutral$138.00ViewTweet This Rating  Share This Rating on StockTwits
11/5/2014JMP SecuritiesReiterated RatingMarket Outperform$200.00 -> $204.00ViewTweet This Rating  Share This Rating on StockTwits
11/5/2014NomuraReiterated RatingBuy$158.00 -> $175.00ViewTweet This Rating  Share This Rating on StockTwits
11/5/2014Morgan StanleyReiterated RatingEqual Weight$103.00 -> $111.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2014Citigroup Inc.Initiated CoverageBuy$145.00ViewTweet This Rating  Share This Rating on StockTwits
10/14/2014Roth CapitalBoost Price TargetBuy$183.00 -> $185.00ViewTweet This Rating  Share This Rating on StockTwits
9/16/2014William BlairBoost Price Target$186.00ViewTweet This Rating  Share This Rating on StockTwits
9/4/2014SunTrustInitiated CoverageNeutral$140.00ViewTweet This Rating  Share This Rating on StockTwits
8/1/2014Deutsche BankReiterated RatingBuy$180.00ViewTweet This Rating  Share This Rating on StockTwits
8/1/2014JPMorgan Chase & Co.Reiterated RatingOverweight$150.00 -> $152.00ViewTweet This Rating  Share This Rating on StockTwits
8/1/2014RBC CapitalBoost Price Target$95.00 -> $100.00ViewTweet This Rating  Share This Rating on StockTwits
8/1/2014Credit SuisseBoost Price Target$121.00 -> $163.00ViewTweet This Rating  Share This Rating on StockTwits
8/1/2014WallachBeth CapitalUpgradeHold -> Buy$160.00ViewTweet This Rating  Share This Rating on StockTwits
7/29/2014Leerink SwannUpgradeMarket Perform -> Outperform$102.00 -> $142.00ViewTweet This Rating  Share This Rating on StockTwits
5/2/2014Piper JaffrayDowngradeOverweight -> NeutralViewTweet This Rating  Share This Rating on StockTwits
4/21/2014Ned Davis ResearchUpgradeSell -> NeutralViewTweet This Rating  Share This Rating on StockTwits
2/21/2014Robert W. BairdBoost Price Target$163.00 -> $173.00ViewTweet This Rating  Share This Rating on StockTwits
11/14/2013WedbushReiterated RatingOutperform$165.00ViewTweet This Rating  Share This Rating on StockTwits
10/30/2013Goldman SachsReiterated RatingBuy$170.00ViewTweet This Rating  Share This Rating on StockTwits
10/4/2013Wells Fargo & Co.Initiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
9/23/2013Lazard Capital MarketsReiterated RatingBuy$141.00ViewTweet This Rating  Share This Rating on StockTwits
4/4/2013TheStreetDowngradeBuy -> HoldViewTweet This Rating  Share This Rating on StockTwits
1/14/2013Lazard LtdDowngradeBuy -> NeutralViewTweet This Rating  Share This Rating on StockTwits
12/7/2012Dawson JamesInitiated CoverageOutperform$101.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 11/26/2012 forward)